Navigation Links
Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
Date:2/14/2012

LEXINGTON, Mass., Feb. 14, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company completed its $4.1 million Series A angel-led financing.  Cherrystone Angels of Providence, Rhode Island led the round, with participation from Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, North Country Angels and other individuals.

Dr. Barbara Fox, Avaxia's founder and CEO, commented, "This investment will allow us to pursue the development of our AVX-470 anti-TNF oral antibody and prepare Avaxia to start treating patients with inflammatory bowel disease in a clinical trial this coming fall.  In addition, the funding we have received from BARDA (Biomedical Advanced Research and Development Authority) to develop AVX-470 for GI Acute Radiation Syndrome provides Avaxia with resources to pursue products and value creation in two important disease areas.  Having broad support from the New England angel community demonstrates the important role that angels are playing in funding early stage biotech companies and provides Avaxia with an investor network for future funding."

The funds from this Series A financing will be used to manufacture the company's orally active anti-TNF for its upcoming clinical trial and to conduct final pre-clinical studies in advance of a Phase 1B clinical trial in patients with inflammatory bowel disease.  Prior to this equity round, the company raised $4.3 million in non-dilutive financing.   In addition to a loan from the Massachusetts Life Sciences Center and several SBIR grants, the company was awarded a $3.0 million, 2 year contract with BARDA that fully funds the initial research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. <
'/>"/>

SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
3. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
4. Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
5. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
6. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
7. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
8. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
9. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
10. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
11. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
(Date:7/24/2014)... July 24, 2014 Your cell ... in modeling lithium-ion battery storage capacity. , New ... a theoretical model created at Lawrence Livermore ... that predicts how carbon components will perform as ... emphasizes the urgent need for higher-performance batteries. Several ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... N.J. , July 24, 2014 ... provider of regulatory and ethical review services for ... Alliance Biosciences. Formerly a division of ... was the leading biosafety and biosecurity consulting firm ... With this addition, WCG,s biosafety division – WCG ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... , , DUBLIN, Ohio, ... to acquire the assets of privately held Biotech, an operator ... the Southwestern United States. , , Cardinal ... pharmacies and operates 26 cyclotron-based PET radiopharmaceutical manufacturing facilities. These ...
... ... for Jatropha Promotion & Biodiesel (CJP) a big breakthrough in the search for a viable ... of successful field trials, CJP is now happy to announce the much awaited commercial release ... ...
... ... Terrosa Technologies, a provider of Cloud and SaaS migration services ... sales, marketing and distribution responsibilities with Integrated Clinical Solutions for ... Trial Management System (CTMS) tool for the pharmaceutical clinical research ...
Cached Biology Technology:Cardinal Health Completes Biotech Acquisition 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 3Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3
(Date:7/24/2014)... arose have been maintained in our cells today according to ... today in the Journal of Biological Chemistry reveals ... animals still perform ancient reactions thought to have been responsible ... ago. , The primordial soup theory suggests that life began ... combination of metals, gases from the atmosphere and some form ...
(Date:7/24/2014)... work with a new drug that successfully treated lupus in ... received a $250,000 grant to expand his research to a ... a wider range of autoimmune diseases., Chandra Mohan, Hugh Roy ... UH, previously published a study in Arthritis Research & Therapy ... lupus in mice and reduced the number of cases of ...
(Date:7/24/2014)... July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric ... its next generation smart wallet, Wocket™, was recently the topic of  ... interviewed Gino Pereira , CEO of NXT-ID, ... Mr. Gino Pereira explains ... of credit cards and walks host Anita Finley ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... turtles have been slow to give up the secrets ... For decades, paleontologists who study fossils and molecular biologists ... more closely related to birds and crocodiles or to ... Biological Laboratory in Bar Harbor, Maine, and their colleagues ...
... Bethesda, Md. (July 25, 2011)It,s no secret that ... a bevy of recent research suggests that these positive ... a new review article highlighting the results of more ... this topic, Michelle W. Voss, of the University of ...
... One of the latest attempts to boost the ... in which patients receive a therapeutic injection of their ... clinical trials for melanoma and neuroblastoma, has its limitations: ... outside the body for future re-injection is extremely expensive ...
Cached Biology News:Discovery places turtles next to lizards on family tree 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 3Universal donor immune cells 2
This Dedicated 18" X 18" (45.7 X 45.7 cm.) shaker platforms are optimized for a particular flask clip size. Dedicated platforms come fully loaded with flask clips....
... VARIOKLAV 75 S and 135 S steam sterilizers ... bottoms combine the advantages of a double-walled device ... effective deaeration and drying by built-in jacket heater ... fast cooling. The chamber is free of furnishings ...
... Shakers combine high durability and performance ... The patented triple-counterbalanced heavy-duty mechanism ... run with heavy out-of-balance loads. ... contamination. The heavy stainless steel ...
... 4300 System features Saga GT , is ... automates electrophoresis, lane finding, location of standards, ... ,Saga GT is second generation software ... initially developed at the University of Washington ...
Biology Products: